All In Biotech

Drug Trial Radar · NCT07668401

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 7, 2027

Primary completion

Jan 11, 2029

Study completion Jan 11, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Conditions

  • Obesity
  • Overweight

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • Placebo ( matched to Zenagamtide)Drug

    Placebo matched to Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to week 80

Locations

44 sites in 5 countries. Site status is shown where the registry gives one.

  • All India Institute of Medical Science (AIIMS), Guwahati

    Assam, India

  • SMS Hospital

    Jaipur, India

  • GMERS Medical college and hospital

    Vadodara, India

  • Nirmal Hospital Pvt. Ltd.

    Surat, Gujarat, India

  • SSG Hospital, Baroda

    Vadodara, Gujarat, India

  • Karnataka Medical College and Research Institute

    Hubbali, Karnataka, India

  • Government Medical College, Kozhikode

    Kozhikode, Kerala, India

  • TOTALL Diabetes Hormone Institute

    Indore, Madhya Pradesh, India

  • Shree Mahalaxmi DIATONE Institute

    Kohlapur, Maharashtra, India

  • Excel Endocrine Centre

    Kolhāpur, Maharashtra, India

  • BSES MG hospital

    Mumbai, Maharashtra, India

  • All India Institute of Medical Sciences (AIIMS), Nagpur

    Nagpur, Maharashtra, India

  • Shalini Tai Meghe Hospital and Research Center

    Nagpur, Maharashtra, India

  • Vijan Hospital & Research Centre

    Nashik, Maharashtra, India

  • Grant Medical Foundation Ruby Hall Clinic

    Pune, Maharashtra, India

  • Chellaram Diabetes Institute

    Pune, Maharashtra, India

  • Maulana Azad Medical College

    Delhi, New Delhi, India

  • Madras Diabetes Research Foundation

    Chennai, Tamil Nadu, India

  • Christian Medical College Hospital, Vellore

    Vellore, Tamil Nadu, India

  • Diabetes Research Center, Hyderabad

    Hyderabad, Telangana, India

  • Osmania General Hospital

    Hyderabad, Telangana, India

  • Kindai University Hospital_Department of Endocrinology, Metabolism and Diabetes

    Sakai-shi, Osaka, Japan

  • Medical Corporation Shinanokai Shinanozaka Clinic_Internal Medicine

    Shinjuku-ku, Tokyo, Japan

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, Japan

  • Fukuwa Clinic_Internal Medicine

    Tokyo, Japan

  • ToCROM Clinic_Internal Medicine

    Tokyo, Japan

  • OCROM Clinic_Internal medicine

    Suita-shi, Osaka, Japan

  • Hospital Melaka

    Malacca, Malaysia

  • Hospital Putrajaya

    Putrajaya, Malaysia

  • Hospital Canselor Tuanku Muhriz UKM

    Cheras, Kuala Lumpur, Malaysia

  • University Malaya Medical Centre

    Lembah Pantai, Kuala Lumpur, Malaysia

  • Hospital Miri

    Miri, Sarawak, Malaysia

  • Kyungpook National University Hospital_Family Medicine

    Daegu, South Korea

  • Seoul National University Hospital_Family Medicine

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System_Family Medicine

    Seoul, South Korea

  • Konkuk University Medical Center_Endocrinology

    Seoul, South Korea

  • Seoul National University Bundang Hospital_Endocrinology

    Seoungnam-si, Gyeonggi-do, South Korea

  • Ajou University Hospital_Family Medicine

    Suwon, Gyeonggi-do, South Korea

  • Pusan National University Yangsan Hospital_Family Medicine

    Yangsan, Gyeongsangnam-do, South Korea

  • Ramathibodi Hospital

    Bangkok, Thailand

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.